English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Ovarian cancer is the most lethal cause of gynecological cancer deaths in the developing world and typically presents at an advanced stage when optimal debulking and platinum based-chemotherapy remain the cornerstone of management. Unfortunately, despite fre‐ quent initial responses to chemotherapy, these tumors almost invariably relapse. Thanks to recent large scale molecular profiling studies in ovarian cancer, such as the integrated ge‐ nomic analyses performed by the Cancer Genome Atlas (TCGA) network, significant head‐ way has been made in our understanding of the molecular pathogenesis of ovarian cancer1. However these advances have failed to translate into meaningful clinical benefit for patients. The only approved novel ‘targeted’ therapy to date in ovarian cancer is the anti-angiogenic antibody, bevacizumab, for which reliable predictive markers still elude us.

The PI3K/Akt/mTOR Pathway in Ovarian Cancer: Biological Rationale and Therapeutic Opportunities